Back to Studies
IMPAACT 2008
Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants
Study Status
Participants Off Study and Primary Analysis Completed
DAIDS Number
20735
IND Number
133,017
Clinical Trials Link
Primary Protocol Team Members
Summary
IMPAACT 2008 is a Phase I/II, multisite, randomized controlled study of monoclonal antibody VRC01 combined with antiretroviral therapy in infants. The study is designed to assess the safety of VRC01 administered with ART (through Week 14) and the effect of VRC01 on HIV-1 DNA concentrations in peripheral blood (at Week 14) among HIV-1-infected infants.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...